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Background: Helicobacter pylori infection poses a risk of the occurrence of gastrointestinal 
diseases, such as gastric cancer. Its incidence rate is significantly reduced by eradication, and 
thereby, eradication therapy is generally performed. Disulfiram is an oral prescription drug 
mainly used for the treatment of alcohol dependence. In recent years, reports have been made 
on its anticancer and antibacterial effects, and thus, it has recently become an interesting 
subject. This study aimed to examine the antibacterial activity of disulfiram, investigate the 
presence or absence of its antibacterial activity on H. pylori, and determine whether it could 
be a new bactericidal drug against drug-resistant H. pylori.
Materials and Methods: Drug-sensitive strains of H. pylori and amoxicillin-resistant, 
clarithromycin-resistant, and metronidazole-resistant strains were used, and a growth inhibi-
tion test of H. pylori using disulfiram was performed. Furthermore, the expression of urease, 
vacuolating cytotoxin A (VacA), and CagA, the virulence proteins of H. pylori, was 
quantitatively analyzed using the Western blotting method. In addition, for H. pylori used 
in this study, the 16SrDNA sequence, a ribosomal gene involved in protein production, was 
analyzed to examine the presence or absence of gene mutation.
Results: Disulfiram suppressed the growth of 7 out of 12 H. pylori strains at 1 µg/mL, and 
no correlation was observed between their susceptibility/resistance to current eradication 
antimicrobial drugs and disulfiram resistance. Disulfiram reduced the expression levels of 
urease, VacA, and CagA proteins. H. pylori, which showed resistance to disulfiram, tended to 
have fewer gene deletions/insertions in the 16S rDNA sequence; however, no specific 
mutation was detected.
Conclusion: Disulfiram has a bactericidal effect on H. pylori at low concentrations, 
suggesting that it can be used as a supplement for current H. pylori eradication drugs.
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Introduction
Helicobacter pylori is a Gram-negative spiral bacterium that inhabits the human 
gastric mucosa. H. pylori infection poses a risk of the occurrence of gastrointestinal 
diseases, such as peptic ulcer, gastric mucosa-associated lymphoid tissue lym-
phoma, and gastric cancer;1–4 however, its occurrence is significantly reduced by 
eradication.5,6 In Japan, eradication therapy using amoxicillin and clarithromycin is 
the primary treatment for H. pylori infection; however, in recent years, the eradica-
tion success rate is decreasing due to the increased incidence of drug-resistant 
H. pylori.7
Disulfiram is an oral administration drug marketed under the trade name 
Antabuse and used primarily indicated for the treatment of alcohol dependence. 
Correspondence: Kenji Yokota  
Graduate School of Health Science 
Okayama University, Okayama, 700-8558, 
Japan  
Tel/Fax +81-86-235-6846  
Email yokochan@md.okayama-u.ac.jp
Infection and Drug Resistance 2021:14 1757–1764                                                         1757
© 2021 Kobatake et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the 
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Infection and Drug Resistance                                                              Dovepress
open access to scientific and medical research
Open Access Full Text Article
Received: 1 March 2021
Accepted: 12 April 2021

































































Powered by TCPDF (www.tcpdf.org)
When disulfiram is orally ingested, one molecule of dis-
ulfiram is converted into two molecules of diethyldithio-
carbamic acid in the gastrointestinal tract and blood and 
further metabolized into diethyldithiocarbamic acid methyl 
ester sulfoxide. When these metabolites react and bind to 
activation sites such as aldehyde dehydrogenase, alcohol 
metabolism is reduced, resulting in hangover symptoms, 
resulting in avoidance of alcohol inoculation.8 Disulfiram 
has been used as a therapeutic agent for alcohol depen-
dence for many years; however, studies have re-focused on 
its anticancer9,10 and antibacterial activities in recent 
years.11,12
Therefore, this study focused on the antibacterial activ-
ity of disulfiram, investigated the presence or absence of 
its antibacterial activity against H. pylori, and investigated 




H. pylori strains were isolated from patients admitted to 
Okayama University Hospital with informed consent. 
Ethical approval to carry out the study was obtained 
a priori from the Okayama University Ethics Committee 
(Number 2034). H. pylori samples were collected in accor-
dance with the 1964 Helsinki declaration and its later 
amendments. E-test was used to measure susceptibility to 
amoxicillin, clarithromycin, and metronidazole for anti-
bacterial sensitivity. If the minimum inhibitory concentra-
tion (MIC) value of amoxicillin is ≥0.1 µg/mL; 
clarithromycin, ≥2 µg/mL; and metronidazole, ≥1 µg/mL, 
the strain is identified as resistant to each antibiotic. Then, 
drug-sensitive, amoxicillin-resistant, clarithromycin- 
resistant, and metronidazole-resistant strains were 
selected. Table 1 shows drug resistance values of the 
selected 12 strains.
H. pylori Growth Inhibition Test with 
Disulfiram
Whether disulfiram suppresses the growth of H. pylori was 
measured. About 20 mL of brain heart infusion (BHI) 
medium containing 5% horse serum was placed in a 50- 
mL liquid culture flask, and the medium was allowed to 
stand in a carbon dioxide (CO2) incubator overnight to 
saturate the liquid medium with CO2. Disulfiram (Sigma- 
Aldrich) was added to a CO2-saturated liquid medium to 
prepare a chemical medium with a disulfiram 
concentration of 10, 5, 1, and 0 µg/mL. As a pre-culture, 
H. pylori, which had been pure-cultured on BHI agar 
medium containing 7% horse defibrosis blood at 37°C 
for 4 days under microaerobic conditions, was suspended 
in a BHI solution containing 5% horse serum at OD600 
=1.0 (108 CFU/mL). H. pylori infused with 500 µL each 
suspended medium was inoculated and cultured by shak-
ing at 37°C under microaerobic conditions for 4 days. 
Absorbance was measured at OD600 nm every day, and 
the bacterial growth was confirmed by increased absor-
bance. Bacterial solution was collected after shaking the 
culture, and morphological changes of the bacteria were 
observed with Gram staining. A portion of the cultured 
medium was applied to the horse blood BHI agar medium 
and cultured at 37°C in microaerobic conditions for 7 days 
to confirm its effects on H. pylori developmental ability.
Protein Expression Level Measurement
The amount of H. pylori was estimated from strain absor-
bance in which the growth of H. pylori was confirmed in the 
growth inhibition test. When OD600 = 0.5, the amount of 
bacteria is approximately 107 CFU/mL. Bacterial solutions 
were collected from media with disulfiram concentrations of 
0 µg/mL and 1 µg/mL by centrifugation. Bacteria were re- 
suspended into distilled water with 1 mM of protease inhi-
bitor phenyl-methyl-sulfonyl fluoride and disrupted by ultra-
sonic waves in ice for 10 min using a device (Bioruptor, 
Cosmobio). A sample was prepared by diluting the same 
amount as the SDS sample buffer and heating at 100°C for 
10 min. About 10 of the prepared sample was added to 1 







S1 <0.016 <0.016 0.047
S2 <0.016 <0.016 <0.016
S3 <0.016 <0.016 0.016
AC1 6 16 0.32
AC2 0.75 1 256<
AC3 256< 256< 16
CH1 0.032 256< 256<
CH2 0.032 256< 256<
CH3 0.023 12 96
MZ1 <0.016 6 0.96
MZ2 0.023 0.75 128
MZ3 <0.016 0.25 48
Abbreviations: MIC, minimum inhibitory concentration; AC, amoxicillin-resistant 
strain; CH, clarithromycin-resistant strain; MZ, metronidazole-resistant strain.
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well, electrophoresed at 90 V for 2 h using the SDS-PAGE, 
and then transferred to a polyvinylidene fluoride (PVDF) 
membrane at 100 mA for 4 h. After the transfer, the PVDF 
membrane was blocked overnight with phosphate-buffered 
saline (PBS) containing 10% skim milk. After washing with 
PBS for 5 min and 3 times, urease (30 kDa) antibody (in 
house), CagA antibody (Funakoshi), or VacA antibody 
(Santa Cruz Biotechnology, Inc) diluted 1000-fold with 
10% skim milk-added PBS were added as primary antibodies 
and shaken for 2 h; horseradish peroxidase-labeled antibody 
(Dako) diluted 1000-fold with 10% skim milk-added PBS 
was added as a secondary antibody and shaken for 1 h; and 
the color was developed by Pierce® Western Blotting 
Substrate (Thermo Fisher Scientific), and the band was 
detected and quantified by chemiluminescence using the 
Amersham Imager 600 (Cytiva).
Confirmation of Gene Mutation
DNA Extraction from the Bacteria
DNA was extracted from the strain according to the product 
protocol of QIAamp DNA Micro Kit (QIAGEN). The bac-
teria were suspended in a 1.5-mL Eppen tube with 500-µL of 
physiological saline and centrifuged at 15,000 rpm for 2 min, 
and the supernatant was discarded. The remaining precipitate 
was pulverized by tapping or vortexing, added with 300 μL 
of Nuclei Lysis Solution, and the mixture was suspended by 
pipetting, incubated at 80°C for 5 min, and cooled at room 
temperature. After adding 1.5 μL of RNase and mixing by 
inversion, the mixture was incubated at 37°C for 15 min and 
cooled at room temperature. Thereafter, 100 μL of protein 
precipitation solution was added, vortexed, and then cooled 
in ice for 5 min. Centrifugation was performed at 4°C and 
15,000 rpm for 3 min, the supernatant was placed in a new 
Eppen tube, and 300 μL of isopropanol was added. 
Thereafter, the mixture was centrifuge at 4°C and 
15,000 rpm for 2 min, the supernatant was discarded, and 
300 μL of 70% ethanol was added. It was centrifuged again at 
4°C and 15,000 rpm for 2 min, and the ethanol in the tube 
was carefully aspirated. After drying the tube at 37°C, 50 μL 
of DNA rehydration solution was added and incubated at 65° 
C for 60 min.
Polymerase Chain Reaction Detection and Sequence
The sequence of 16S rDNA, a ribosomal gene involved in 
protein production, was detected by polymerase chain 
reaction (PCR) using primers 16S-F and 16S-R. The 
sequence of each primer is shown in Table 2.
Using the DNA of the extracted bacteria as a template, 
PCR was performed in a total amount of 50 µL. TaKaRa 
Ex Taq (5 units/µL) of 0.5 µL; 10 × Ex Taq Buffer, 5.0 µL; 
dNTP mixture (2.5 mM each), 4.0 µL; template, 1.0 µL; 
primer pair, 1.0 µL; sterile distilled water, 38 µL were 
mixed. PCR conditions were 98°C for 1-min denaturation, 
98°C for 10 s, 60°C for 30 s, and 72°C for 30 s for 35 
cycles. A 5-µL PCR product was electrophoresed on a 2% 
agarose gel for 30 min. The gel after migration was stained 
with ethidium bromide for 20 min and observed by ultra-
violet irradiation using an electrophoresis gel imaging 
device Dolphin-View (Dolphin-View, Kurabo, Japan). 
The DNA sample amplified by PCR was purified using 
the ethanol precipitation method. The sequence was out-
sourced to the Hokkaido System Science Co., Ltd. 
Samples were sequenced using the PRISM3130 Genetic 
Analyzer (Applied Biosystems), and sequence data were 
analyzed with GENETYX software.
Statistical Analysis
Statistical analysis of H. pylori protein expression level 
measurement was performed using t-test. The P-value of 
<0.05 was considered statistically significant.
Results
H. pylori Growth Inhibition Test with 
Disulfiram
Whether disulfiram inhibits the growth of H. pylori was 
examined using a total of 12 strains. All strains underwent 
complete growth inhibition in the media with disulfiram con-
centrations of 10 µg/mL and 5 µg/mL. In the drug-sensitive 
(Figure 1A) and clarithromycin-resistant strains (Figure 1C), 
two strains were suppressed in growth in a medium with 
a disulfiram concentration of 1 µg/mL, and one strain grew 
from the third day of culture. In the metronidazole-resistant 
strain (Figure 1D), two strains were suppressed in growth in 
a medium with a disulfiram concentration of 1 µg/mL, and 
one strain grew from the 4th day of culture. Among the 
amoxicillin-resistant strains (Figure 1B), one strain underwent 
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Figure 1 Inhibition of H. pylori growth at a disulfiram concentration of 1 µg/mL. (A) Drug-sensitive strain, (B) amoxicillin-resistant strain, (C) clarithromycin-resistant strain, 
and (D) metronidazole-resistant strain. The vertical axis represents the absorbance at OD600 nm, and the horizontal axis represents the number of days of the culture. 
Numbers in parentheses indicate the disulfiram concentration (µg/mL). 
Abbreviations: S, drug-sensitive strain; AC, amoxicillin-resistant strain; CH, clarithromycin-resistant strain; MZ, metronidazole-resistant strain.
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growth inhibition in a medium with a disulfiram concentration 
of 1 µg/mL, and one strain grew from the 4th day of culture, 
and another one strain grew from the 1st day of culture. No 
correlation was found between susceptibility/resistance to 
current disinfectants and disulfiram resistance. After collect-
ing the bacterial solution after shaking the culture and obser-
ving the morphological changes of the bacteria using the 
Gram stain, the spiral shape was lost and the bacteria changed 
to a short rod-like (Figure 2A and B). In addition, when 
applied to BHI agar medium with 7% horse blood and cul-
tured at 37°C for 7 days, the amount of colonies was smaller 
than the usual growth (Figure 2C and D).
H. pylori Pathogenic Protein Expression 
Level Measurement
Bacterial proteins were compared with a disulfiram concen-
tration of 0 µg/mL and 1 µg/mL using one from each of the 
drug-sensitive, amoxicillin-resistant, clarithromycin- 
resistant, and metronidazole-resistant strain with growth 
confirmed in the growth inhibition test. The increase/ 
decrease in urease, VacA, and CagA protein expressions 
levels in each bacterium was measured. In the drug- 
sensitive strain, protein expression levels of all three species 
decreased, and a significant difference was observed 
between urease and VacA (Figure 3A). Amoxicillin- 
resistant strains had significantly reduced protein expression 
levels in all three species (Figure 3B). In the clarithromycin- 
resistant strain, protein expression levels of all three species 
decreased, and a significant difference was observed in 
urease (Figure 3C). In the metronidazole-resistant strain, 
expression levels of urease and VacA decreased and that of 
CagA increased, and no significant difference was observed 
among the three species (Figure 3D).
Confirmation of Gene Mutation
For all 12 H. pylori strains used, the sequence of 16SrDNA, 
a ribosomal gene involved in protein production, was ana-
lyzed, and the presence or absence of gene mutation was 
examined. Table 3 shows the number of base substitutions 
and the number of deletions/insertions in the 16SrDNA 
Figure 2 Bacterial morphology and colonies. (A) Morphology of H. pylori growth in BHI broth without disulfiram, (B) morphology of H. pylori with 1μg of disulfiram. After 
cultivation in broth, bacteria were inoculated on BHI agar. (C) Colony of H. pylori transferred from BHI broth without disulfiram, (D) colony of H. pylori transferred from BHI 
broth with 1μg of disulfiram.
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sequence. Of these, susceptible strain 3 (S3), amoxicillin- 
resistant strain 1 (AC1), amoxicillin-resistant strain 2 (AC2), 
clarithromycin-resistant strain 1 (CH1), and metronidazole- 
resistant strain 2 (MZ2) were resistant to disulfiram in the 
growth suppression test. Strains resistant to disulfiram 
tended to have fewer base deletions/insertions.
Discussion
Eradication therapy using amoxicillin and clarithromycin 
is performed for H. pylori infection, a risk factor for the 
occurrence of gastrointestinal diseases such as gastric 
cancer. However, in recent years, a decrease in the eradi-
cation success rate due to an increase in drug-resistant 
strains has become a problem, and further increase in 
drug-resistant strains and the emergence of resistant strains 
to new antibiotics should be prevented.13
Disulfiram is an oral prescription drug mainly used as 
a therapeutic drug for alcohol dependence and is usually 
taken orally in 1–3 divided doses of 100–500 mg daily, 
and the maintenance dose is 100–200 mg.8 In this study, 
disulfiram suppressed the growth of 11 among 12 strains at 
a concentration of 1 µg/mL at 2 days of H. pylori culture 
Figure 3 H. pylori pathogenic protein expression level. (A) Drug-sensitive strain, (B) amoxicillin-resistant strain, (C) clarithromycin-resistant strain, and (D) metronidazole- 
resistant strain. The vertical axis represents the protein expression level.
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and 7 at 4 days of culture. In addition, H. pylori acted on 
disulfiram showed poor growth of colonies in 7% horse 
blood BHI agar medium, and the cells lost their spiral 
shape and became short rod-like. Based on these facts, 
disulfiram is considered to exhibit an antibacterial effect 
against H. pylori at a low concentration regardless of the 
sensitivity and resistance to the current H. pylori eradica-
tion drug.
Urease, VacA, and CagA are important proteins with 
pathogenic effect in the stomach. H. pylori, which neutralized 
gastric acid with urease, secretes VacA, a cell-vacuolating 
toxin, destroys host cells, and secretes CagA protein to pro-
mote carcinogenesis of host cells.14 In this study, the expres-
sion levels of urease, VacA, and CagA proteins decreased in 
H. pylori infection treated with disulfiram. Based on the results 
of the growth inhibition test, disulfiram is considered to exhibit 
a concentration-dependent bactericidal action by inhibiting 
protein synthesis of H. pylori.
16SrDNA is a ribosomal gene involved in protein 
production, and this sequence of approximately 1500 
bases is used for bacterial phylogeny. The 16SrDNA 
sequence is abundantly registered in public databases and 
is considered suitable for examining sequences specific to 
a particular bacterial species/group.15,16 When 16SrDNA 
mutations were confirmed in all 12 H. pylori strains used 
in this study, strains showing disulfiram resistance tended 
to possess fewer base deletions/insertions but were suscep-
tible/resistant to disulfiram. No specific mutations due to 
differences were detected. Most of these deletions/inser-
tions were found in domain 2 (V4 region) of 16SrDNA, 
and we cannot find that this fact is important or associate 
with protein production. For clearer features, the number 
of samples should be increased, and further study 
conducted.
Conclusion
Although the genetic characteristics on the effectiveness of 
disulfiram against H. pylori can be further investigated, it 
exhibited a bactericidal effect on H. pylori at a lower 
concentration than when used as a supplemental drug. 
Therefore, disulfiram could be used as an adjunct to the 
current H. pylori eradication drug.
Abbreviations
AC, amoxicillin; CH, clarithromycin; MZ, metronidazole; 
BHI, brain heart infusion; MIC, minimum inhibitory con-
centration; PCR, polymerase chain reaction.
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